Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically relating to the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
- September 28, 2006: 16,122 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
- October 11, 2006: 8,370 Ordinary shares were purchased on behalf of an Annual Investment Plan participant at GBP 14.59 per share.
- October 11, 2006: 4,298 Ordinary shares were transferred to a participant in the Annual Investment Plan.
- October 11, 2006: 532 Ordinary shares were purchased on behalf of a Bonus Investment Plan participant at GBP 14.59 per share.
Management Commentary and Risks
The filing notes that the Trust is a discretionary fund for non-US employees and former employees. Director Mr. J S Heslop holds an interest in the shares held in the fund similar to other eligible employees. The transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b). No specific risks, contingencies, or unusual items regarding the company's operations are detailed in this text.
Investor Verification Points
- Verify the total volume of shares transferred or purchased under the Annual and Bonus Investment Plans during the reporting period.
- Confirm the transaction price of GBP 14.59 per share against market data for October 11, 2006.
- Review the full composition of the SmithKline Beecham Employee Benefit Trust to understand the scope of Director J S Heslop's indirect interest.